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Poly (D,L-Lactic-co-Glycolic acid) (PLGA) is a biodegradable and biocompatible polymer approved by 
FDA for clinical uses. Surface functionalization of self-assembly micelles made of PLGA with Poly-
Ethylene Glycol (PEG) improves its stability and half-life in blood circulation via inhibiting adsorption of 
proteins on the surface and consequently decreasing opsonization rate. The purpose of present study was 
to optimize PEG amount absorbed on PLGA (PEGabsPLGA) micelles by application of quality by design 
approach. Based on risk assessment, effect of three variables including PLGA concentration, PEG 
concentration and molecular weight (MW) of PLGA were studied. Central composite design was 
implemented for design of experimentation with 26 runs. The PEGabsPLGA nano drug delivery system 
(NDDS), produced by o/w method, was optimized according to particle size, polydispersity index (PDI) 
and zeta potential values. Validation of the model was successfully performed with three representative 
formulations from the design space. As a result, 43.79 mg of PLGA with MW of 30,000-60,000 was 
incorporated with 12.61 mg of PEG to obtain a 69 nm NDDS (predicted 67.72 nm) with the PDI value 
equal to 0.124 (predicted 0.112). The results successfully led to the preparation of the most stable 
nanoparticles which were stable at room temperature for six months. 




Drug delivery systems (DDS) have been introduced to increase the effectiveness of a drug system through 
increasing the permeability, solubility and metabolic stability of a drug molecule [1]. DDS are the results 
of interdisciplinary research which combines different fields such as polymer science, pharmaceutics and 
molecular biology [2].  DDS are basically designed to transport pharmaceutical agents to the systemic 
circulation and to control the pharmacokinetics, pharmacodynamics, non-immunogenicity, non-specific 
toxicity and bio-recognition of target site [3]. DDS are more advantageous than traditional systems in 
their tendency to deliver the pharmaceutical agents more selectively to a desired site, elimination of over- 
or underdosing, increase in patient compliance, prevention of side effects and consistent absorption within 
the desired cell [4].   
Ideal polymeric DDS should have specific properties such as adequate drug loading, compatibility with 
the drug, proper molecular weight and controlled release [5]. These properties are important in the 
prevention of rapid body clearance and the creation of affinity to cell surface and receptors to allow 
pinocytic uptake by the target cells. These properties are favorable for selective targeting, stability, non-
immunogenicity, reproducible zero-order drug release, controlled biodegradability and non-toxicity [5]. 
At the moment, no such ideal DDS exist that reveal all these characteristics. Nevertheless, an acceptable 
product with approximate zero-order release and controlled degradation kinetics can be achieved through 
physicochemical modification of the polymer or the drug. To reach this purpose, an array of research is 
being conducted to develop biodegradable polymeric nanoparticles specifically designed for drug delivery 
[6]. Poly (lactic-co-glycolic acid) (PLGA) is one of the most effectively used biodegradable polymers in 
this process which is able to form nano sized micelles in aqueous media. PLGA has been approved by the 
US FDA and the European Medicines Agency (EMA) in varying DDS in humans [7-9]. But, the body 
treats hydrophobic particles as foreign and the reticulo-endothelial system (RES) removes these from the 
blood stream and takes them up in the liver or the spleen [10]. This is one of the most significant 
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biological obstacles to nanoparticle-based controlled drug delivery. To address these limitations, a 
number of methods of surface modifications have been developed to create nanoparticles that are not 
recognized by the RES. Nano-micelles can be coated with molecules that conceal the hydrophobicity by 
providing a hydrophilic layer at the surface [11]. The most general method for surface modification is use 
of the hydrophilic and non-ionic polymer polyethylene glycol (PEG) [12, 13]. The existence of PEG on 
the PLGA nanomicelles imparts extra functionality through the use of polymeric nanoparticles [14]. Some 
studies suggest synthesis of PLGA–PEG–PLGA nano-micells [15].  
Considering these facts, the main objective of this study is to optimize a nano drug delivery system using 
PEG absorbed on PLGA (PEGabsPLGA) by application of quality by design (QbD) approach. We 
specifically aimed to develop PEGabsPLGA nanomicellar formulations using a QbD approach to 
understand the influences of formulation and process parameters on the critical quality attributes (CQAs) 
of these nanoparticles and to establish a design space. Since the process of absorption of PEG on micelles 
doesn’t contain any complex chemical reactions, it may be used for a better adoption of commercial 
chemotherapeutic nano drug delivery systems. 
In a QbD study, the main purpose is to develop a detailed process and product understanding, which can 
be reached through well-established design of experiment tools [16]. Conventional experimental methods 
have many disadvantages. Changing a single experimental factor at a time and keeping other factors 
constant leads to more experiments and makes the process non-feasible [17]. Furthermore, this eliminates 
the possibility of evaluating factor interactions. Statistical experimental designs (DoE) provide more 
accurate results with fewer runs compared with the conventional approaches. In addition, optimization of 
product and process is possible by DoE based on extrapolation of data and plotting of the results [18]. 
There are several experimental designs in the literature that can be applied to reduce the number of 
studies while obtaining more useful data [19]. If the goal is to mathematically estimate a response or to 
precisely optimize a process, models such as Central Composite Design (CCD) are used. This design has 
been used in the current study.   
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2. MATERIALS AND METHODS
2.1. Materials 
Poly Ethylene Glycol-2000 methyl ether (# 202509), PLGA (Lactide:Glycolide ratio of 50:50), with 
molecular weights of 30,000-60,000 (High) (#P2191) and 24,000-38,000 (Low)(#739952) were 
purchased from Sigma-Aldrich USA. Acetone, ethanol and Tween 80 were purchased from Merck 
(#8.22187.0500), Darmstadt, Germany. 
2.2. Experimental design 
PEGabsPLGA drug delivery system was optimized by the response surface methodology. According to 
preliminary studies and literature review [20-22], PLGA amount, PEG amount and PLGA molecular 
weight were selected as three important factors. Three factors were studied at 5 different levels (-α, -1, 0, 
+1, +α) using a CCD. The α value of 1.414 was chosen to maintain rotatability and orthogonality of the
design. Total 26 experiments were carried out with 10 center points, 8 axial points and 8 cube points 
(Table 1). 
Table 1. Selected variables in central composite design 
Factors Levels 
X1: PLGA amount (mg) 43.79 50 65 80 86.21 
X2: PEG amount (mg) 1.89 5 12.5 20 23.11 




Minitab 17 (Minitab Inc.; State College, PA, USA) software was used for experiment design and 
statistical analysis. Response was predicted by two quadratic polynomial equations, each one representing 
one of the two levels (shown by i) of the categorical variable (i.e., PLGA molecular weight):  




where Yi is the response for each level of PLGA molecular weight (i.e., Low and High) , X1 and X2 are 
the main effects of factors, X1 2 is the interaction effects of factors, 
 and 
 are quadratic effects of 
factors, β0 is the constant, and β1 and β2 are the coefficients of the factors. Analysis of variance (ANOVA) 
was performed to evaluate the effect of independent variables on the responses, and P=0.05 was 
considered to be statistically significant. Predicted (pred.) and adjusted (adj.) correlation coefficient (R2) 
was calculated to evaluate the fitness of model. After generating the polynomial equations regarding the 
factors and responses, formulation and process were optimized with respect to average particle size (Y1), 
zeta potential (Y2) and PDI (Y3) of the PEGabsPLGA nano drug delivery system using the developed 
mathematical model to determine the levels of PLGA amount (X1) and PEG amount (X2) and PLGA 
molecular weight (X3). For this, a design space was constructed using several contour plots and response 
surface graphs. The optimized drug delivery system formulation was prepared and tested to evaluate the 
correlation between the predicted and the actual values of the responses. The optimum formulation was 
further characterized for its physicochemical properties. 
2.3. Preparation of the Drug Delivery System 
The preparation of nanoparticles was based on simple oil-in-water (o/w) emulsification-solvent 
evaporation method [23]. Briefly, PEG and PLGA were dissolved in 5 ml of acetone based on Table 2. 
The obtained solvents were mixed and dropped into 20 ml stirring aqueous phase containing 1 ml of 
homogenized (0.05%) Tween 80 and 19 ml water. 
Acetone was evaporated overnight. The resulting suspension containing PEGabsPLGA nanoparticles 
were reached to 20 ml with distilled water and were kept at 25°C for further tests.  
2.4. Determination of Particle Size (PS), Polydispersity Index (PDI) and Zeta Potential (ZP) 
PS and PDI of nanoparticles were determined by dynamic light scattering (DLS) technique using 
Zetasizer (model ZEN 3600; Malvern Instrument, Inc., London, UK) at 25oC. Default setting on the 
Zetasizer was used, i.e. refractive index of 1.59, absorption of 0.010, water as the dispersant and 
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measurement angle of 173. Measurements were repeated 5 times, 3 minutes each and data were analyzed 
by number, intensity and volume distribution, however, the “zeta average” reported by the operating 
system of the zetasizer was used in QDB calculations [24]. ZP was determined by laser Doppler micro-
electrophoresis method by using a folded capillary zeta cell (Malvern Instruments Ltd).  
2.5. Fourier Transform Infrared Spectroscopy  
To evaluate molecular state of PEG and PLGA, Fourier transform infrared (FTIR) spectra of PEG, PLGA, 
PEGabsPLGA nanoparticles were recorded on an alpha platinum ATR (Bruker; USA) using 25 scans. 
Measurements were conducted at room temperature between 400 and 4000 cm−1 [1 ]. 
2.6. Atomic Force Microscopy 
Atomic force microscopy (AFM) study was performed to evaluate the particle shape, size, and 
distribution of nanoparticles. For AFM imaging, a High performance AFM (NanoMagnetics, Ankara, 
Turkey) equipped with a PPP-NCLAuD cantilever in dynamic mode was used. In order to stabilize the 
particles on mica, an origami buffer was used. A droplet of origami buffer was bedded on the mica and 
after 30 minutes, a droplet of formulation was added and imaged after 30 minutes [25, 26]. 
2.7. Stability Studies 
Stability of optimized formulation was evaluated during storage at 25°C for 60 days. PS and PDI, ZP 
were measured as described.  
2.8. Determination the Amount of PEG Incorporated with PLGA 
Self-assembly is defined as “processes that involve pre-existing components, are reversible, and can 
be controlled by the proper design of the components” [27]. Thus systems such as PEG-PLGA are 
equilibrated reversible systems. In such systems the hydrophobic and hydrophilic chains dissolve in 
aqueous media in an amount equal to their water solubility. Excess amount incorporates with other 
chains to make self-assembly systems. The chains in aqueous media continuously enter to the 
micellar system and leave it. Thus, continuously there are constant amount of amphiphilic materials 
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outside of the micelles in aqueous media. Previously it has been shown that the materials which are 
not incorporated in the structure of micelles could be separated from them by centrifugation in high 
speed and low temperature [28]. The optimized particle was prepared according to above mentioned 
method. After evaporation of acetone the volume of the system was recovered to 20ml using distilled 
water and centrifuged at 4oC, 38,203 × g for 10 min. Supernatants were collected and lyophilized at -
80oC and 0.03 mbar. Obtained fluffy material was weighted and accepted as the constant amount of 
polymeric material not incorporated with micelles. The experiment was repeated in triplicates and  the 
FTIR spectra of dried supernatant was recorded to verify its chemical structure.      
3. RESULTS
3.1. Experimental Design 
3.1.1. Design Model and Data Analysis 
CCD setup and obtained responses from a total of 26 experiments are presented in Table 2. The model fit 
was assessed and the results showed good model fit for size and PDI. However, for Zeta potential, lack of 
fit of the model (p=0.0302) was significant. In other words, the model was not suitable in prediction of 
Zeta potential and Zeta potential was not included in the optimization process.  
The following quadratic, second-order equations were used to predict the minimum particle size for the 
PEGabsPLGA nano drug delivery system: 
When PLGA molecular weight is 30,000-60,000 (High): 
Y1,1 = -144.2 + 5.92 X1 + 3.46 X2 - 0.0324 X1X2 - 0.0348 
 - 0.0413
 
When PLGA molecular weight is 24,000-38,000 (Low):  
Y2,2 = -109.2 + + 5.54 X1 + 2.82 X2 - 0.0324 X1X2 - 0.0348 
 - 0.0413 
 
where Y1,1 and Y2,2 are particle size for different levels of PLGA molecular weight, while X1 and X2 are 
coded values for PLGA amount and PEG amount, respectively. Regression model was tested by ANOVA 
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as presented for average size in Table 3. According to the results, a low p value (0.005) indicated that the 
model equation was statistically significant. Lack-of-fit value of the model was statistically insignificant 
(p=2.85), which implies that the model fits well. Confidence level of the regression model was verified by 
a coefficient R2 value of 0.6737 that indicated 67.37% of variability in the response can be explained by 
this model.  
The following second equation was used to predict the minimize PDI for the PEGabsPLGA nano drug 
delivery system: 
When PLGA molecular weight is 30,000-60,000 (High): 
Y3,1 = 0.840 - 0.02068 X1 - 0.02502 X2 + 0.000211 X1X2 + 0.000154 
 - 0.04 + 0.000517 
 
When PLGA molecular weight is 24,000-38,000 (Low):  
Y3,2 = 1.033 - 0.02335 X1 - 0.02715 X2 + 0.000211 X1X2 + 0.000154 
  + 0.000517 
 
where Y3,1 and Y3,2 are PDI for different levels of PLGA molecular weight, while X1 and X2 are coded 
values for PLGA amount and PEG amount, respectively. The low p value (0.022) implied the significance 
of the model equation as displayed in Table 4. Lack of fit of the model (p=0.286) was not significant. 
According to the coefficient R2 value of 0.5975, 59.75% of variability in PDI could be explained by the 
model.      
Table 2. Central Composite Design Experimental Matrix (X1: PLGA amount (mg), X2: PEG amount (mg) 
and X3: PLGA molecular weight *) 
variable Responses 
Run X1 X2 X3 Av. Z Zeta PDI 
CCD1 65.00 12.50 Low 102.50 20.90 0.10 
CCD2 65.00 12.50 Low 107.80 13.80 0.09 
CCD3 43.79 12.50 Low 86.73 30.67 0.10 
CCD4 65.00 12.50 Low 105.60 24.17 0.09 
CCD5 80.00 5.00 Low 119.60 22.87 0.12 
CCD6 65.00 12.50 High 109.30 5.81 0.11 
CCD7 50.00 20.00 High 74.75 8.90 0.14 
CCD8 65.00 12.50 Low 113.00 26.80 0.10 
CCD9 65.00 12.50 High 107.90 5.85 0.11 
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CCD10 80.00 5.00 High 102.20 5.62 0.17 
CCD11 65.00 12.50 Low 90.48 23.13 0.10 
CCD12 65.00 12.50 High 111.70 6.10 0.01 
CCD13 65.00 12.50 High 115.90 6.67 0.01 
CCD14 50.00 20.00 Low 87.17 33.17 0.14 
CCD15 80.00 20.00 Low 98.40 29.43 0.15 
CCD16 50.00 5.00 Low 90.02 23.87 0.21 
CCD17 86.21 12.50 Low 110.30 36.80 0.09 
CCD18 50.00 5.00 High 60.10 9.39 0.12 
CCD19 65.00 23.11 High 111.90 7.63 0.12 
CCD20 65.00 23.11 Low 98.04 24.50 0.12 
CCD21 43.79 12.50 High 70.93 0.23 0.14 
CCD22 65.00 1.89 Low 94.60 0.47 0.11 
CCD23 80.00 20.00 High 106.00 6.85 0.26 
CCD24 86.21 12.50 High 104.00 5.71 0.19 
CCD25 65.00 1.89 High 111.40 6.64 0.13 
CCD26 65.00 12.50 High 91.08 3.18 0.10 
*: Low: 24,000-38,000, High: 30,000-60,000 
Table 3. ANOVA results for PDI 








Model 0.039 8 0.005 3.15 0.022 
X1 0.001 1 0.001 0.82 0.377 
X2 0.000 1 0.000 0.18 0.678 
X3 0.000 1 0.000 0.2 0.659 

 0.017 1 0.017 10.77 0.004 

 0.012 1 0.012 7.61 0.013 
X1X2 0.005 1 0.005 2.92 0.106 
X1X3 0.006 1 0.006 4.16 0.057 
X2X3 0.001 1 0.001 0.67 0.426 
Lack of fit 0.017 9 0.002 1.51 0.286 
Pure error 0.010 8 0.001 3.15 0.022 
Total 0.065 25 
Table 4. ANOVA results for size 








Model 3592.16 8 449.02 4.39 0.005 
X1 2358.58 1 2358.58 23.04 0 
X2 0 1 0 0 0.999 
X3 28.2 1 28.2 0.28 0.606 

 850.79 1 850.79 8.31 0.01 

 75.04 1 75.04 0.73 0.404 
X1X2 106.58 1 106.58 1.04 0.322 
X1X3 132.11 1 132.11 1.29 0.272 
X2X3 91.88 1 91.88 0.9 0.357 
Lack of fit 1096.29 9 121.81 1.51 0.285 
Pure error 643.66 8 80.46 4.39 0.005 
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Total 5332.1 25 
3.1.2. Optimization Study  
Optimum conditions were determined by Minitab 17 software based on the obtained results from CCD 
study. Desired limits were set as minimized size and PDI. Coded variables for optimized formulation 
were found as X1=43.79, X2=12.60 and X3=High. 
Three-dimensional surface and contour plots for PDI and size as a function of PEG amount and PLGA 
amount with PLGA molecular weight fixed as high are presented in Fig. 1.  
Fig. 1. Contour and response surface plots showing the effects of PLGA amount and PEG amount (while 
PLGA molecular weight is fixed as 30,000-60,000 (High)) on the average particle size and PDI of the 
PLGA-PEG drug delivery system. 
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The optimized formulation (i.e., PLGA amount =43.79, PEG amount =12.61 and PLGA molecular weight 
=High) was prepared in triplicate to evaluate the model accuracy for the optimum conditions. Predicted 
and experimental responses for optimized variables are presented in Table 5. Observed experimental 
values were in close agreement with the predicted values. Coordination between the results indicated the 
significance and validity of the model.  
Table 5. The Observed and the Predicted Values of the Optimum PEGabsPLGA Nano Drug Delivery 
System Based on Desirability Function 
Response Observed Predicted Residual 
Particle size (nm) 69.0 67.72 1.28 
PDI 0.124 0.112 0.012 
3.1.3. Determination of Particle Size (PS), Polydispersity Index (PDI) and Zeta Potential (ZP) 
PS, PDI and ZP measurements were conducted for all nanoparticle formulations prepared for studying the 
experimental design. PLGA and PEG amount ranging from 43.79 to 86.21 and 1.88 to 23.11, 
respectively, led to obtaining nanoparticles with size distribution between 60.10 and 119.60 nm, while 
PDI of these nanoparticle was below 0.213, revealing narrow size distribution and uniform particle 
formation. ZP results varied between -0.23 and −36.80 mV, which shows direct dependence of this value 
on the PEG amount. The results of optimized formulation were verified three times at laboratory. Fig. 2 
shows results of one of them.  
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Fig.2: DLS results of particle size distribution of optimized formulation measured in terms of a: % 
intensity: 80 nm , b: %number: 45 nm, c: %volume: 58 nm and : zeta potential: -5.76 mv and finally e:
time history of particle sizing all of which, indicates obtaining mono-dispersed particles with no hidden 
aggregates 
PS is an important parameter for membrane penetration in all systemic and local applications and it has 
been investigated by different research groups to determine its optimum range. Generally, it has been 
concluded that particles below 200 nm are sufficient for delivery to deeper layers [29-31]. 
3.2. Fourier Transform Infrared Spectroscopy 
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To investigate the interaction between PEG and PLGA, FTIR spectra of PEG, PLGA, PEGabsPLGA 
nanoparticles were acquired (Fig. 3). In the spectrum of  PEG, the regular PEG absorption band around 
3450 cm-1 showing the OH stretching band is absent due to the methoxide derivative which was used in 
formulation process. The aliphatic C-H stretching bands at 2881 cm-1, C-H bending vibrations at 1466 
and 1341 cm-1 and C-O-C stretching vibrations at 1279 and 1005 cm-1 were observed, which are 
consistent with the data in the previous reports [32]. At the FTIR spectra of PLGA, the peak generated by 
symmetrical and asymmetrical stretching of CH2 and CH3 groups between 2980 and 2949 cm
-1 were the 
most significant ones, while bands of C=O stretching (1745 cm-1) asymmetrical deformation of CH3 were 
presented in 1375cm-1 and CH2 in 1450 cm
-1 were also presented. The regular C-O stretching of aliphatic 
polyesters are also presented in 1165 cm-1 and the 1083 cm-1 [33].  
While all above mentioned peaks of PEG and PLGA are presented in spectra of PEGabsPLGA nano-
particles as well, there are some minor changes and shifts by which it is possible to conclude the 
successful incorporation of these two polymer with each other and also the regions of which they are 
incorporated. The C-H and/or CH3 stretching bands of PLGA and PEG have been shifted from 2881 and 
2949 to 2923-2850 combining at a single region. The decrease at the intensity of C-H stretching peak of 
PEG and increase in that of PLGA reveals the incorporation of these two polymers in an inclusive 
manner. Not only the hydrophilic glycolic units of PLGA are interacted (represented by the CH2 
stretching peaks) but also the hydrophobic lactic members are incorporated with PEG. The very small 
shifting of the peaks at this region to lower wavelength shows the firm incorporation between PLGA and 
PEG with consequently causes need of higher energy for the C-H bonds to be stretched. This is where the 
C=O stretching peak of PLGA has been up-shifted to 1752 points at the ease of bending this bond by IR, 
which could be caused by occupying the aliphatic regions of PLGA by PEG which consequently causes 
the free stretching of this carbonyl group. 
ACCEPTED MANUSCRIPT
ACCEPTED MANUSCRIPT
Fig. 3: IR results of A) PEG B) PLGA, C) PEGabsPLGA and D) the chemical composition of 
supernatants for determination of amount of PEG and PLGA incorporated  
3.3.  Atomic Force Microscopy 
AFM study was performed to evaluate the particle shape, size, and distribution of PEGabsPLGA 
nanoparticles (Fig. 4). The nanoparticles were found to be spherical, nonporous, smooth, and 
homogenously dispersed. The particle size distribution of nanoparticles showed correlation with the 
results obtained from DLS studies, i.e., ≈45nm. 
Fig. 4: AFM a: topography and b: histogram of optimized formulation of PEGabsPLGA 
nanoparticles indicating the particle size ≈ 45nm  
3.4.  Stability studies 
PS, PDI and ZP changes of formulations stored at 25°C during 60 days were monitored. PS, PDI and ZP 
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of particles after 60 days are shown in Fig.5. There is not any considerable change in PS and ZP.  PDI is 
slightly increased with time but it is still completely mono-dispersed. Fig. 6 shows the results of 
optimized formulation after 60 days. 
3.5. Determination the Amount of PEG Incorporated with PLGA 
Some studies use polymers to decrease the surface tension of water and ease the micelle formation. These 
polymers must be removed from the system to avoid toxicity. Polyvinyl alcohol is one of those polymers. 
It has been shown that centrifuge at high speed and low temperature is able to remove PVA from system 
without causing any disruption in micellar structures [28]. Thus we centrifuged the optimized formulation 
and separated the supernatants to understand the composition and amount of the PEG and/or PLGA which 
are not incorporated with micelles in a certain period of time. As we mentioned in Optimization Study 
results the optimized formulation is consisted of 43.79 mg of PLGA with MW of 30,000-60,000 and 
12.61 mg PEG. Since each 20 ml of formulation contains almost 3 mg of Tween 80 the optimized 
formulation is totally weighted 59.4 mg. The amount of supernatant was around 22.2 mg which is almost 
37.4% of whoe materials used.   
FTIR studies showed that both PLGA and PEG are presented in the lyophilized supernatant (Figure 3, D). 
The higher intensity of peaks related to PEG in mixture shows that the amount of PEG is higher than 
PLGA in mixture. This shows that almost 37.4% of the polymeric material is continuously exchanged 
between micellar aggregates and aqueous media and not only hydrophilic PEG is attended in this 
exchange but also amphiphilic PLGA is circulated inside and out of micelles as well.     
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Fig. 5: DLS results of optimized formulation after 60 days of incubation at room temperature measured in 
terms of a: % intensity: 83 nm, b: %number: 40 nm, c: %volume: 56 nm and : zeta potential: -5.06 mv 
and finally e: time history of particle sizing all of which, indicate stability of obtained optimized nano-
micelle at the end of stability studies 
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4. DISCUSSION
While there are numerous studies made on PLGA-PEG NDDS, the optimized ratio of absorbed PEG to
PLGA is not explored yet. Koopaei et. al [34] have chemically conjugated PLGA (50:50, MW 4800) with 
PEG 5000. They have optimized the process of nanoparticle preparation, by choosing the polymer 
concentration, drug concentration and ratio of the organic to aqueous solvent as the independent variables 
to obtain particles with size of 118nm. Probably using the PEG with MW much higher than the one in our 
study is what has caused obtaining particles with bigger size. However, the ratio of PEG to PLGA has 
been chosen as a constant (1:4, W/W) and it was not included in optimization process [34]. In another 
study, ocular administration of dexibuprofen using PEGylated PLGA Diblock copolymer nanospheres has 
been optimized according to pH, drug and surfactant concentrations as variables while the amount of 
polymer was kept constant (90 mg) [35]. This study has emphasized the importance of pH in production 
of mono-dispersed NDDS consisted of PLGA-PEG and the size of obtained particles is reported as “under 
200 nm” which is much higher than currently reporting data. However, their results regarding reduction in 
the zeta potential of NDDS from -20mV [36] to -5 mV by PEGylation of PLGA micelles is in complete 
agreement with our current study.  
In the current study, the validity of obtained results has been tested by chasing the stability of produced 
nano-micelles for six months. The size and mono disperse behaviour of nano-micelles was considered as 
the determinants of stability. The symmetrical shape of size diagrams obtained from DLS indicates the 
spherical shape of all produced nano-micelles [37, 38]. Neither their shape nor their size does not show 
any difference at the stability assay time period.  
Regarding the dominance of the intensity and the volume of the light scattered by shapeless aggregates 
compared to that of spherical particles [38],  the presence of aggregation in the aqueous system could be 
best detected by %volume and %intensity distribution measurements. The mono-disperse behaviour of 
obtained optimised PEGabsPLGA nano-micelle was evidenced using these parameters, which showed the 
same profile at the beginning and the end of stability assay.  
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As it is well known, the amphiphilic materials such as PLGA form self-assembly systems in aqueous 
media [39]. Particles made by these systems are consisted in the presence of water and disassociate upon 
drying. To the best of our knowledge, the AFM imaging of a self-assembly system is performed in this 
study for the first time by using origami buffer. The results of particle size obtained from AFM assay of 
the optimised formulation is in well coordination with DLS results as ≈ 45nm.  
Results obtained from responses of variables X1 (PLGA amount (mg)), X2 (PEG amount (mg)) and 
X3 (PLGA molecular weight) show that the size of nano-micelles increases in accordance with the 
increase in the amount of PLGA, not with its MW. In other words, 65 mg low MW PLGA with 12.5 mg 
PEG results in obtaining 102.5 nm particles while, the same amounts of PEG with low MW 86.21 mg 
PLGA results in obtaining 110.3 nm particles. However, same amounts of high MW PLGA and PEG 
result in obtaining 104.00 nm particles.  
The results of FTIR indicate the complete incorporation of PLGA with PEG in all functional group 
regions. Thus, we report the complete incorporation of PLGA with PEG resulting in formation of mono 
dispersed stable particles, which provides a suitable base for uploading hydrophobic drug molecules.      
5. CONCLUSION
In this study, the effects of formulation and process variables on the properties of PEG-PLGA drug
delivery system were evaluated by the use of Central Composite Design. The physicochemical tests such 
as FTIR revealed the complete interaction of PLGA and PEG chains by involving all of their functional 
groups in this mutual effect.  The stability studies showed that the optimized drug delivery system was 
sufficiently stable. The same method can be applied for the development of other drug delivery systems in 
order to increase bioavailability and circulation time in the body. Hundreds of tumour targeting and/or 
sustained release nano formulations have been developed based on PLGA nano micelles, which obviously 
would face problems such as opsonisation and fast clearance in body. Replacement of PLGA with PEG 
chemically conjugated PLGA would cause basic modifications in these formulations, thus, here in this 
study we presented the optimized amount of PEG which is needed to be absorbed on certain amount of 
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PLGA without any need for chemical reactions. 
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